Vaxcyte Business Summary

Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company that generates revenue through the development and future commercialization of high-fidelity vaccines, primarily leveraging its proprietary XpressCF® cell-free protein synthesis platform licensed from Sutro Biopharma. The company’s business model is centered on its pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-31 (a 31-valent candidate in Phase 3) and VAX-24 (a 24-valent candidate). While currently pre-revenue from product sales, Vaxcyte maintains a robust capital position through public equity offerings—most recently closing a $632.5 million offering in February 2026—and potential future milestone or royalty payments. In the competitive landscape, Vaxcyte acts as a high-valency disruptor against established pharmaceutical giants Pfizer (Prevnar 20), Merck & Co. (Capvaxive), and GSK. The company distinguishes itself by targeting a broader range of serotypes (31 versus the current 20-21 standard) to address serotype replacement and provide superior protection against invasive pneumococcal disease. Vaxcyte was co-founded by CEO Grant Pickering and VP of Research Jeff Fairman, PhD, both of whom previously led Juvaris BioTherapeutics. Pickering brings over 30 years of experience from leadership roles at Mymetics and Kleiner Perkins, while Fairman is a veteran of platform-based vaccine research. The executive team includes President and CFO Andrew Guggenhime, formerly of Dermira; EVP and COO Jim Wassil, who held senior vaccine roles at Pfizer and GSK; and Chief Commercial Officer Mike Mullette, who joined in late 2025 from Moderna. Other key leaders include Chief Business and Strategy Officer Chris Griffith and Chief Technical Operations Officer Harp Dhaliwal. The company’s board is chaired by Dr. Carlos Paya and features notable industry veterans such as Dr. Olivier Brandicourt, the former CEO of Sanofi, and John Furey. Vaxcyte is backed by a high concentration of institutional investors, including Fidelity (Fmr LLC), RA Capital Management, Vanguard, and BlackRock.